Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting

NCT04425200 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04425200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04425200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
July 29, 2020
Completion date
December 18, 2020
Enrollment
205 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasms